Emerging Markets Earnings Roundup: Merck, Pfizer And Amgen (Part 3)
This article was originally published in PharmAsia News
Executive Summary
Pfizer lowers overall growth guidance for emerging markets this year but remains bullish on prospects for growth as EMs become more like mature markets in reimbursement and overall health care policies. Merck meanwhile emphasized cost-cutting measures and Amgen sets its sights on Japan.